How many insider trades does FilingIQ track for AUTL?

FilingIQ tracks 18 Form 4 insider transactions for AUTL (Autolus Therapeutics plc), covering filings from Jun 29, 2026 onwards. 18 of those were filed in the last 90 days.

Are AUTL insiders net buyers or net sellers?

Across the full Form 4 history for AUTL, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AUTL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is AUTL in?

Autolus Therapeutics plc (AUTL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $452.44M.

AUTL insider trading

NasdaqGS Healthcare

Autolus Therapeutics plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$452.44M

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Company website: www.autolus.com

AUTL insider activity at a glance

FilingIQ has scored 18 insider transactions for AUTL since Jun 29, 2026. The most recent filing in our index is dated Jun 29, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live AUTL trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 983

UNITED THERAPEUTICS Corp

NUVL 195

Nuvalent, Inc.

KYMR 193

Kymera Therapeutics, Inc.

GH 192

Guardant Health, Inc.

Hims & Hers Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for AUTL?: FilingIQ tracks 18 Form 4 insider transactions for AUTL (Autolus Therapeutics plc), covering filings from Jun 29, 2026 onwards. 18 of those were filed in the last 90 days.
Are AUTL insiders net buyers or net sellers?: Across the full Form 4 history for AUTL, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AUTL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AUTL in?: Autolus Therapeutics plc (AUTL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $452.44M.

Methodology & sources

Every AUTL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.